Pharmacopeia — Pharmacopeia Drug Discovery — Wall Street Analyst Forum 2004
21 slides from Pharmacopeia's conference presentation, Dec 1, 2004

Slide 1: Wall Street Analyst Forum
; PHARMACOPEIA DRAUG DISCOVERY Wall Street Analyst Forum Leslie J. Browne, President & CEO December ist, 2004 The Roosevelt Hotel, New York, NY 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 2: Forward-looking Statements
Forward-looking Statements When used anywhere in this presentation, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating res

Slide 3: New Opportunity
, PHARMACOPEIA DRUG DISCOVERY New Opportunity Pharmacopeia Drug Discovery, Inc. is a biopharmaceutical company, focused on the creation of new small molecule therapeutics for significant unmet medical needs 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 4: Strategic Value Capture Points
Strategic Value Capture Points Hi Market Value products Lo Lo Investment (Time, $, IP) 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 5: Build stockholder value
Build stockholder value Raise Pharmacopeia profile Maintain existing customer base Evolve the business model Sow seeds for future growth 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 6: Strategy
Strategy Maintain and evolve current collaboration business while increasing investment in internally funded therapeutic programs to build the portfolio Raise Pharmacopeia profile Maintain existing business Evolve the business model Sow seeds for future growth Communicate the opportunity Raise scien

Slide 7: Focused internally on Immunobiology
Focused internally on Immunobiology ISdO3BWHBHd & Au3009510 nua Rheumatoid Arthritis Psoriasis Ulcerative Colitis Inflammatory Bowel Disease

Slide 8: Robust Pipeline
Robust Pipeline In Vitro Lead Optimization ©) In Clinical Trials w/ Collaborators 4 Lead Discovery 20+ 443809510 9nWG ISdO3BWHBHd &

Slide 9: Product Portfolio - November 2004
Product Portfolio - November 2004 Predinioal Glinioa Phase Lead Generation | Optimization [ evelopment 7 Program | Partner 75616808 | Rheunaoid | erstol yee Arhiteres | Saubb Peaseees | Aathmanleray | bait PSiaDHGD | Respiratory | Scheing Plough Peaaiea | Intammaton | Scheine Plough Pse0a0e8 | Oncac

Slide 10: p38 MAP Kinase Inhibition
p38 MAP Kinase Inhibition * P38 is a member of the MAP kinase superfamily * Independent activation pathway responsive to stress stimuli: — inflammatory cytokines, endotoxin, osmotic, UV, chemical stress * Regulates production of inflammatory cytokines — TNF-a, IL-1, IL-6, IL-8 4U3009510 9NuG gage bi

Slide 11: P38 kinase: Central Role in Inflammation
P38 kinase: Central Role in Inflammation RA — anti-TNFo Enbrel Remicade Humira Blocks the inflammatory effects of TNF & IL-1 PS 516895 in clinical Phase | 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 12: Biologics Rheumatoid Arthritis Market
Biologics Rheumatoid Arthritis Market Enbrel Arava Kineret Humira AmgenAWyeth Remicade J&J Aventis Amgen Abbott Source: Projected 2000 2004 2002 2003 2004 2005 652 761 802 1590 2,250 2,900 369 724 1,297 1,561 1966 = 2,173 7 2341 266 237 119 59 - 12 62 125 200 235 = 5 - 200 475 698 1,198 1725 2427 93

Slide 13: Physiology and Pathology of avB3
iL, 2. Physiology and Pathology of avB3 Role in Angiogenesis avp3 is expressed on i. retinal vasculature of patients with Age-related Macular Degeneration (AMD) ii. vascular endothelial cells from patients with Proliferative Diabetic Retinopathy (PDR) avp3 expression is linked to neoplastic progress

Slide 14: Pharmacopeia avB3 binding and cell assay data
4U3009510 9NuG gage bisdO2BWEOHd Gee Pharmacopeia | avp3 Binding | Cell Adhesion | Migration Proliferation Ic50 (um) | 1c50 (uM) | Ic50 (uM) Ic50 (uM) 680648 780035 388023 NA - Not Active; ND — non Dose Responsive

Slide 15: searchable text of slide shown abov e
searchable text of slide shown abov e

Slide 16: Inhibition of hypoxia-induced retinal neovascularization by PS388023
Inhibition of hypoxia-induced retinal Vehicle neovascularization by PS388023 cRGD PS388023 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 17: searchable text of slide shown abov e
searchable text of slide shown abov e

Slide 18: Business Evolution
PHARMACOPEIA DRUG DISCOVERY Business Evolution

Slide 19: Collaboration milestones and alliances
9/27/04 Pharmacopeia Delivers Leads and Triggers Research Milestone in Collaboration with Neurocrine 10/5/04 Pharmacopeia Achieves Preclinical Development Candidate Milestone in Collaboration with Schering-Plough 10/26/04 Biovitrum AB and Pharmacopeia Form Strategic Research Alliance 4U3009510 9NuG

Slide 20: The Next months
The Next 12 months Continuing milestone flow from collaborations Expanded product portfolio Partnered programs should advance Addition of key pre-clinical and clinical assets Internal programs towards preclinical development 4U3009510 9NuG gage bisdO2BWEOHd Gee

Slide 21: Searchable
Searchable text section of graphics shown above [ LOG O] [LOGO] Wall Street Analyst Forum Leslie J. Browne, President & CEO December 1st, 2004 The Roosevelt Hotel, New York, NY For ward-looking Statements When used anywhere in this presentation, the words expects, believes, anticipates, estimates, a
Source: SEC EDGAR · 8-K filed Dec 1, 2004
More decks from Pharmacopeia Inc
Pharmacopeia — Merger or Acquisition (November 2008)34 slides · Nov 3, 2008
The Oppenheimer 19th Annual Healthcare Conference (November 2008)33 slides · Nov 3, 2008
Ligand Pharmaceuticals — Merger or Acquisition (September 2008)18 slides · Sep 24, 2008
BMO Capital Markets 7th Annual Focus on Healthcare Conference 200822 slides · Aug 5, 2008
Investor Presentation (May 2008)36 slides · May 19, 2008
Investor Presentation (May 2008)11 slides · May 16, 2008